MDXH trades 2527.0% below Wall Street's consensus target of $15.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MDXH achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, MDxHealth S.A. (MDXH) has a Wall Street consensus price target of $15.00, based on estimates from 6 covering analysts. With the stock currently trading at $0.57, this represents a potential upside of +2527.0%. The company has a market capitalization of $29M.
Analyst price targets range from a low of $15.00 to a high of $15.00, representing a 0% spread in expectations. The median target of $15.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MDXH trades at a trailing P/E of -0.9x. Analysts expect EPS to grow +63.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 VCYTVeracyte, Inc. | $3.7B | $45.81 | $57.43 | +25.4% | Buy | 23.9x | 22 |
 NTRANatera, Inc. | $58.8B | $410.35 | $350.07 | -14.7% | Buy | — | 28 |
 QDELQuidelOrtho Corporation | $734M | $10.77 | $12.25 | +13.7% | Hold | 13.9x | 15 |
 ILMNIllumina, Inc. | $41.3B | $273.04 | $237.00 | -13.2% | Buy | 51.0x | 50 |
 PACBPacific Biosciences of California, Inc. | $789M | $2.54 | $1.18 | -53.5% | Buy | — | 18 |
 CDNACareDx, Inc | $3.5B | $67.15 | $62.25 | -7.3% | Buy | 56.1x | 13 |
 PRMEPrime Medicine, Inc. | $538M | $2.98 | $7.50 | +151.7% | Buy | — | 10 |
 LHLabcorp Holdings Inc. | $25.3B | $308.49 | $340.75 | +10.5% | Buy | 16.8x | 35 |
 DGXQuest Diagnostics Incorporated | $25.7B | $233.24 | $248.57 | +6.6% | Hold | 20.8x | 34 |
Quick answers to the most common questions about buying MDXH stock.
The consensus Wall Street price target for MDXH is $15, representing 2527.0% upside from the current price of $0.571. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MDXH has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $15 implies 2527.0% upside from current levels.
MDXH's current price is $0.571 with a consensus target of $15 (2527.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $15 for MDXH, while the most conservative target is $15. The consensus of $15 represents the median expectation. These targets typically reflect 12-month expectations.
MDXH is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MDXH stock forecast based on 6 Wall Street analysts shows a consensus price target of $15, with estimates ranging from $15 (bear case) to $15 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MDXH, with a "Buy" consensus rating and $15 price target (2527.0% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MDXH analyst price targets range from $15 to $15, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.